FLT3 and acute myelogenous leukemia: Biology, clinical significance and therapeutic applications

Current Pharmaceutical Design

Volumn 11, Issue 26, 2005, Pages 3449-3457

  Advani, Anjali S ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Acute myelogenous leukemia; FLT3 inhibitors; FLT3 mutations; Targeted therapy

Indexed keywords

4 [6 METHOXY 7 [3 (1 PIPERIDINYL)PROPOXY] 4 QUINAZOLINYL] 1 PIPERAZINECARBOXYLIC ACID (4 ISOPROPOXYPHENYL)AMIDE; 6,7 DIMETHOXY 2 PHENYLQUINOXALINE; 6,7 DIMETHYL 2 PHENYLQUINOXALINE; CEP 701; CP 701; DAUNORUBICIN; ETOPOSIDE; FLT3 LIGAND; GELDANAMYCIN; HERBIMYCIN A; MIDOSTAURIN; MITOXANTRONE; PROTEIN TYROSINE KINASE INHIBITOR; SEMAXANIB; STAT5 PROTEIN; SU 5614; SUNITINIB; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ASTHENIA; BLOOD CELL COUNT; CANCER SURVIVAL; CELL DIFFERENTIATION; CLINICAL FEATURE; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG MECHANISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG TARGETING; EDEMA; FATIGUE; FEVER; GENE EXPRESSION; GENE IDENTIFICATION; GENE MUTATION; HEADACHE; HUMAN; IN VITRO STUDY; INJECTION PAIN; LARYNX DISORDER; LEG EDEMA; LEUKEMOGENESIS; LIVER DYSFUNCTION; MOLECULAR MECHANICS; MUSCLE WEAKNESS; NAUSEA; NONHUMAN; ORBIT; PHLEBITIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SIDE EFFECT; SOLID TUMOR; VOMITING;

CLINICAL TRIALS; FMS-LIKE TYROSINE KINASE 3; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE;

EID: 24944460366     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161205774370807     Document Type: Review

References (97)

1. Miller KB, Daoust PR. Clinical manifestations of acute myeloid leukemia. In: Hematology: Basic Principles and Practice. Churchill Livingston 2000; 2017-18.
2. Frohling S, Schlenck RF, Breitruck J, Benner A, Kreitmeier S, Tobis K, et al. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood 2002; 100: 4372-80.
3. Abu-Duhier FM, Goodeve AC, Wilson GA, Care RS, Peake IR, Reilly JT. Genomic structure of human FLT3: implications for mutational analysis. Brit J Haematol 2001; 113: 1076-7.
4. Agnes F, Shamoon B, Dina C, Rosnet O, Birnbaum D, Galibert F. Genomic structure of the downstream part of the human FLT3 gene: exon/intron structure conservation among genes encoding receptor tyrosine kinases (RTK) of subclass III. Gene 1994; 148: 283-8.
5. Matthews W, Jordan CT, Wiegand GW, Pardoll D, Lemischka IR. A receptor tyrosine kinase specific to hematopoietic stem and progenitor cell-enriched populations. Cell 1991; 65: 1143-52.
6. Naoe T, Kiyoi H, Yamamoto Y, Minami Y, Yamamoto K, Ueda R, et al. FLT3 tyrosine kinase as a target molecule for selective antileukemic therapy. Cancer Chemotherapy and Pharmacology 2001; 48 (Suppl 1): S27-30.
7. Hunter T. Signalling - 2000 and beyond. Cell 2000; 100: 113.
8. Xu F, Taki T, Yang HW, Hanada R, Hongo T, Ohnishi H, et al. Tandem duplication of the FLT3 gene is found in acute lymphoblastic leukaemia as well as acute myeloid leukaemia but not in myelodysplastic syndrome or juvenile chronic myelogenous leukaemia in children. Brit J Haematol 1999; 105: 155-62.
9. Lyman SD, James L, Vanden Bos T, de Vries P, Brasel K, Glinlak B, et al. Molecular cloning of a ligand for the flt3/flk-2 tyrosine kinase receptor: a proliferative factor for primitive hematopoietic cells. Cell 1993; 75: 1157.
10. Schlessinger J. Cell signalling by receptor tyrosine kinases. Cell 2000; 103: 211.
11. Voutsudakis IA. Flt3 in acute myelogenous leukemia. Med Oncol 2003; 20: 311-23.
12. Lavagna-Sevenier C, Murchetto S, Birnbaum D, Rosnet O. FLT3 signaling in hematopoietic cells involves CBL, SHC, and an unknown P115 as prominent tyrosine phosphorylated substrates. Leukemia 1998; 12: 301-10.
13. Scheijen B, Griffin JD. Tyrosine kinase oncogenes in normal hematopoiesis and hematologic disease. Oncogene 2002; 21: 3314-33.
14. Mizuki M, Fenski R, Halfter H, Matsumura I, Schmidt R, Muller C, et al. Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. Blood 2000. 96: 3907-14.
15. Kerkhoff E, Rapp UR. Cell cycle targets of Ras/Raf signaling. Oncogene 1998; 17: 1457-62.
16. Reuther GW, Der CJ. The Ras branch of small GTPases: Ras family members don't fall far from the tree. Curr Opin Cell Biol 2000; 12: 157-65.
17. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nature Rev. Cancer 2002; 2: 489-501.
18. Cardone MH, Roy N, Stennicke HR, Salvesen GS, Franke TF, Stanbridge E, et al. Regulation of cell death protease caspase-9 by phosphorylation. Science 1998; 282: 1318-21.
19. Rane SG, Reddy EP. JAKs, STATs, and Src kinases in hematopoiesis. Oncogene 2002; 3334-58.
20. Reilly JT. FLT3 and its role in the pathogenesis of acute myeloid leukaemia. Leuk Lymphoma 2003; 44: 1-7.
21. Nakao M, Yokota S, Iwai T, Kaneko H, Horiike S, Kashima K, et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 1996; 10: 1911-18.
22. Abu-Duhier FM, Goodeve AC, Wilson GA, Gari MA, Peake IR, Rees DC, et al. FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk group. Br J Haematol 2000; 111: 190-5.
23. Kiyoi H, Naoe T, Nakano Y, Yokota S, Minami S, Miyawaki S, et al. Prognostic implications of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood 1999; 93: 3074-80.
24. Kottaridis PD, Gale RE, Frew ME, Harrison G, Langabeer SE, Belton AA, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 2001; 98: 1752-9.
25. Rombouts WJC, Blokland I, Lowenberg B, Ploemacher RE. Biological characteristics and prognosis of adult acute myeloid leukemia with internal tandem duplications in the Flt3 gene. Leukemia 2000; 14: 675-83.
26. Rombouts WJ, Broyl A, Martens AC, Slater R, Ploemacher RE. Human acute myeloid leukemia cells with internal tandem duplications in the Flt3 gene show reduced proliferative ability in stroma supported long-term cultures. Leukemia 1999; 13: 1071-8.
27. Whitman SP, Archer KJ, Feng L, Baldus C, Becknell B, Carlson BD, et al. Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a Cancer and Leukemia Group B study. Cancer Res 2001; 61: 7233-9.
28. Yokota S, Kiyoi H, Nakao M, Iwai T, Misawa S, Okuda T, et al. Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies: a study on a large series of patients and cell lines. Leukemia 1997; 11: 1605-9.
29. Abu-Duhier FM, Goodeve AC, Wilson GA, Care RS, Peake IR, Reilly JT. Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia. Br J Haematol 2001; 113: 983-8.
30. Yamamoto Y, Kiyoi H, Nakano Y, Suzuki R, Kodera Y, Miyawaki S, et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 2001; 97: 2434-9.
31. Griffin JD. Point mutations in the FLT3 gene in AML (editorial). Blood 2001; 97: 2193.
32. Lisovsky M, Estrov Z, Zhang X, Consoli U, Sanchez-Williams G, Snell V, et al. Flt3 ligand stimulates proliferation and inhibits apoptosis of acute myeloid leukemia cells: regulation of Bcl-2 and Bax. Blood 1996; 88: 3987-97.
33. Bagrintseva K, Schwab R, Kohl TM, Schnittger S, Eichenlaub S, Ellwart JW, et al. Mutations in the tyrosine kinase domain of FLT3 define a new molecular mechanism of acquired drug resistance to PTK inhibitors in FLT3-ITD-transformed hematopoietic cells. Blood 2004; 103: 2266-75.
34. Spiekermann K, Bagrintseva K, Schoch C, Haferlach T, Hiddemann W, Schnittger S. A new and recurrent activating length mutation in exon 20 of the FLT3 gene in acute myeloid leukemia. Blood 2002; 100: 3423-25.
35. Grundler R, Thiede C, Miething C, Steudel C, Peschel C, Duyster J. Sensitivity toward tyrosine kinase inhibitors varies between different activating mutations of the FLT3 receptor. Blood 2003; 102: 646-51.
36. Meshinchi S, Woods WG, Stirewalt DL, Sweetser DA, Buckley JD, Tjoa TK, et al. Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia. Blood 2001; 97: 89-94.
37. Kondo M, Horibe K, Takahashi Y, Matsumoto K, Fukuda M, Inaba J, et al. Prognostic value of internal tandem duplication of the FLT3 gene in childhood acute myelogenous leukemia. Med Pediatr Oncol 1999; 33: 525-9.
38. Bloomfield CD, Lawrence D, Byrd JC, Carroll A, Pettenati MJ, Tantravahi R, et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic risk subgroup. Cancer Res 1998; 58: 4173-9.
39. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1, 612 patients entered into the MRC AML 10 trial. Blood 1998; 92: 2322-33.
40. Slovak ML, Kopecky KJ, Cassileth PA, Harrington DH, Theil KS, Mohamed A, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology group study. Blood 2000; 97: 4075-83.
41. Kottaridis PD, Gale RE, Linch DC. Prognostic implications of the presence of FLT3 mutations in patients with acute myeloid leukemia. Leukemia and Lymphoma 2003; 44: 905-13.
42. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997; 3: 730-7.
43. Shih LY, Huang CF, Wu JH, Lin TL, Dunn P, Wang PN, et al. Internal tandem duplication of FLT3 in relapsed acute myeloid leukemia: a comparative analysis of bone marrow samples from 108 adult patients at diagnosis and relapse. Blood 2003; 2387-92.
44. Brown P, Small D. Flt3 inhibitors: a paradigm for the development of targeted therapeutics for paediatric cancer. European Journal of Cancer 2004; 40: 707-21.
45. Thiede C, Steudel C, Mohr B, Schaich M, Schakel U, Platzbecker U, et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 2002; 99: 4326-35.
46. Moreno I, Martin G, Bolufer P, Barragan E, Rueda E, Roman J, et al. Incidence and prognostic value of FLT3 internal tandem duplication and D835 mutations in acute myeloid leukemia. Haematologica 2003; 88: 19-24.
47. Velby OP, Lyman SD, Jacobsen SE. Combined signaling through interleukin-7 receptors and flt3 but not c-kit potently and selectively promotes B-cell commitment and differentiation from uncommitted murine bone marrow progenitor cells. Blood 1996; 88: 1256-65.
48. Iwai T, Yokoto S, Nakao M, Okamoto T, Taniwaki M, Onodera N, et al. Internal tandem duplication of the FLT3 gene and clinical evaluation in childhood acute myeloid leukaemia. Leukaemia 1999; 13: 38-43.
49. Stirewalt DL, Kopecky KJ, Meschinchi S, Appelbaum FR, Slovak ML, Willman CL, et al. FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukaemia. Blood 2001; 97: 3589-95.
50. Zwaan CM, Meshinchi S, Radich JP, Verrman AJP, Huismans DR, Munske L, et al. FLT3 internal tandem duplication in 234 children with acute myeloid leukemia: prognostic significance and relation to cellular drug resistance. Blood 2003; 102: 2387-94.
51. Boissel N, Cayuela JM, Preudhomme C, Thomas X, Grardel N, Fund X, et al. Prognostic significance of FLT3 internal tandem repeat in patients with de novo acute myeloid leukemia treated with reinforced courses of chemotherapy. Leukemia 2002; 16: 1699-1704.
52. Frohling S, Breitruck J, Schlenk R, Kreitmeier S, Tobis K, et al. FLT3 internal tandem duplications and survival in adult acute myeloid leukemia: analysis of 188 intensively treated patients. Blood 2001; 98: 717a.
53. Zheng R, Levis M, Piloto O, Brown B, Baldwin BR, Gorin NC, et al. FLT3 ligand causes autocrine signaling in acute myeloid leukemia cells. Blood 2004; 103: 267-74.
54. Drexler HG. Expression of FLT3 receptor and response to FLT3 ligand by leukemic cells. Leukemia 1996; 10: 588-99.
55. Carow CE, Levenstein M, Kaufmann SH, Chen J, Amin S, Rockwell P, et al. Expression of the hematopoietic growth factor receptor FLT3 (STK-1/Flk2) in human leukemias. Blood 1996; 87: 1089-96.
56. Rosnet O, Buhring HJ, Marchetto S, Rappold I, Lavagna C, Sainty D, et al. Human FLT3/FLK2 receptor tyrosine kinase is expressed at the surface of normal and malignant hematopoietic cells. Leukemia 1996; 10: 238-48.
57. Birg F, Courcoul M, Rosnet O, Bardin F, Pebusque MJ, Marchetto S, et al. Expresison of the FMS/KIT-like gene FLT3 in human acute leukemias of the myeloid and lymphoid lineages. Blood 1992; 80: 2584-93.
58. Ozeki K, Kiyoi H, Hirose Y, Iwai M, Ninomiya M, Kodera Y, et al. Biologic and clinical significance of the FLT3 transcript level in acute myeloid leukemia. Blood 2004; 103: 1901-8.
59. Hayakawa F, Towatari M, Kiyoi H, Tanimoto M, Kitamura T, Saito H, et al. Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines. Oncogene 2000; 19: 624-31.
60. Spiekermann K, Dirschinger RJ, Schwab R, Bagrintseva K, Faber F, Buske C, et al. The protein tyrosine kinase inhibitor SU5614 inhibits FLT3 and induces growth arrest and apoptosis in AML-derived cell lines expressing a constitutively activated FLT3. Blood 2003; 101: 1494-1504.
61. Spiekermann K, Schwab R, Pau M, Schmieja K, Franrahe S, Hiddemann W. Constitutive activation of STAT3 and STAT5 is induced by leukemic fusion proteins with protein tyrosine kinase activity and is sufficient for transformation of hematopoietic precursor cells. Experimental Hematology 2002; 30: 262-71.
62. Schwaller J, Parganas E, Wang D, Cain D, Aster JC, Williams IR, et al. Stat5 is essential for the myelo- and lymphoproliferative disease induced by TEL/JAK2. Molecular Cell 2000; 6: 693-704.
63. Minami Y, Yamamoto K, Kiyoi H, Ueda R, Saito H, Tomoki N. Different antiapoptotic pathways between wild-type and mutated FLT3: insights into therapeutic targets in leukemia. Blood 2003; 102: 2969-75.
64. Zhen R, Friedman AD, Levis M, Li L, Weir EG, Small D. Internal tandem duplication mutation of FLT3 blocks myeloid differentiation through suppression of C/EBPα expression. Blood 2004; 103: 1883-90.
65. Tse KF, Mukherjee G, Small D. Constitutive activation of FLT3 stimulates multiple intracellular signal transducers and results in transformation. Leukemia 2000; 14: 1766-76.
66. Hawley TS, Fong AZC, Greisser H, Lyman SD, Hawley RG. Leukemia predisposition of mice transplanted with gene-modified precursors expressing flt3 ligand. Blood 1998; 92: 2003-11.
67. Smith BD, Levis M, Beran M, Giles F, Kantarjian H, Berg K, et al. Single agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood 2004 (prepublished online January 15, 2004).
68. Tse KF, Novelli E, Civin CI, Bohmer FD, Small D. Inhibition of the transforming activity of FLT3 internal tandem duplication mutants from AML patients by a tyrosine kinase inhibitor. Leukemia 2002; 16: 2027-36.
69. Levis M, Allebach J, Tse KF, Zheng R, Baldwin BR, Smith BD, et al. A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. Blood 2002; 99: 3885-91.
70. Kelly LM, Liu Q, Kutok JL, Williams IR, Boulton C, Gilliland DG. FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a nurine bone marrow transplant model. Blood 2002; 99: 310-18.
71. Kelly LM, Kutok JL, Williams IR, Boulton CL, Amaral SM, Curley DP, et al. PML/RARα and FLT3-ITD induce an APL-like disease in a mouse model. Proc Natl Acad Sci USA 2002; 99: 8283-8.
72. Levis M, Tse KF, Smith BD, Garrett E, Small D. A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations. Blood 2001; 98: 885-7.
73. O'Farrell AM, Abrams TJ, Yuen HA, Ngai TJ, Louie SG, Yee KW, et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003; 101: 3597-3605.
74. Teller S, Kramer D, Bohmer SA, Tse KF, Small D, Mahboobi S, et al. Bis (1H-2-indolyl)-1-methanones as inhibitors of the hematopoietic tyrosine kinase Flt3. Leukemia 2002; 16: 1528-34.
75. Tse KF, Novelli E, Civin CI, Bohmer FD, Small D. Inhibition of FLT3-mediated transformation by use of a tyrosine kinase inhibitor. Leukemia 2001; 15: 100-10.
76. Yee KW, O'Farrell AM, Smolich BD, Cherrington JM, McMahon G, Wait CL, et al. SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase. Blood 2002; 100: 2941-9.
77. Zheng R, Friedman AD, Small D. Targeted inhibition of FLT3 overcomes the block to myeloid differentiation in 32Dc13 cells caused by expression of FLT3/ITD mutations. Blood 2002; 100: 4154-61.
78. Weisberg E, Boulton C, Kelly LM, Manley P, Fabbro D, Meyer T, et al. Inhibition of mutant FLT3 receptors in leukemia cells by the small molecular tyrosine kinase inhibitor PKC412. Cancer Cell 2002; 1: 433-43.
79. Kelly LM, Yu JC, Boulton CL, Apatira M, Li J, Sullivan CM, et al. CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML). Cancer Cell 2002; 1: 421-32.
80. Kovalenko M, Ronnstrand L, Heldin CH, Loubtchenkov M, Gazit A, Levitzki A, et al. Phosphorylation site-specific inhibition of platelet-derived growth factor B-receptor autophosphorylation by the receptor blocking tyrphostin AG1297. Biochemistry 1997; 36: 6260-9.
81. Levis MJ, Pham R, Small D. CEP-701, a selective FLT3 tyrosine kinase inhibitor that is cytotoxic to FLT3/ITD-expressing leukemia cells, is synergistic with chemotherapeutic agents in vitro when used in time-sequential fashion. Blood 2003; 102: 66a.
82. Propper DJ, McDonald AC, Man A, Thavasu P, Balkwill F, Braybrooke JP, et al. Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C. J Clin Oncol 2001; 19: 1485-92.
83. Stone RM, Klimek V, De Angelo EJ, Nimer S, Estey E, Galinsky I, et al. PKC412, an oral FLT3 inhibitor, has activity in mutant FLT3 acute myeloid leukemia (AML): a phase II clinical trial. Blood 2002; 100: 86a.
84. Stopeck A, Sheldon M, Vahedian M, Cropp G, Gosalia R, Hannah A. Results of a Phase I dose-escalating study of the antiangiogenic agent, SU5416, in patients with advanced malignancies. Clin Cancer Res 2002; 8: 2798-805.
85. Heinrich MC, Druker BJ, Curtin PT, Paquette R, Sawyers CL, De Angelo DJ, et al. A first in man study of the safety and PK/PD of an oral FLT3 inhibitor (MLN518) in patients with AML or high risk myelodysplasia. Blood 2002; 100: 336-7a.
86. De Angelo DJ, Stone RM, Bruner RJ, Caligiuri MA, Heaney ML, Nimer SD, et al. Phase I clinical results with MLN518, a novel FLT3 antagonist: tolerability, pharmacokinetics, and pharmacodynamics. Blood 2003; 102: 65-6a.
87. Foran J, Paquette R, Cooper M, Jacobs M, O'Farrell AM, Kim H, et al. A Phase I study of repeated oral dosing with SU11248 for the treatment of patients with acute myeloid leukemia who have failed, or are not eligible for, conventional chemotherapy. Blood 2002; 100: 558-9a.
88. Kottaridis PD, Gale RE, Langabeer SE, Frew ME, Bowen DT, Linch DC. Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors. Blood 2002; 100: 2383-8.
89. Schnittger S, Schoch C, Dugas M, Kern W, Staib P, Wuchter C, et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood 2002; 100: 59-66.
90. Other Recommended Review Articles:
91. Levis M, Small D. FLT3: ITDoes matter. Leukemia 2003; 17: 1738-52.
92. Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood 2002; 100: 1532-42.
93. Stirewalt DL, Radich JP. The role of FLT3 hematopoietic malignancies. Nat Rev Cancer 2003; 3: 650-65.
94. Lyman SD, Jacobsen SE. C-kit ligand and FLT3 ligand: stem/progenitor cell factors with overlapping yet distinct activities. Blood 1998; 91: 1101-34.
95. Levis M, Small D. Small molecule FLT3 tyrosine kinase inhibitors. Curr Pharm Design 2004; 10(11): 1183-93.
96. Schmidt-Arras D, Schwable J, Bohmer FD, Serve H. Flt3 receptor tyrosine kinase as a drug target in leukemia. Curr Pharm Design 2004; 10(16): 1867-83.
97. Warmuth M, Damoiseaux R, Liu Y, Fabbro D, Gray N. SRC family kinases: potential targets for the treatment of human cancer and leukemia. Curr Pharm Design 2003; 9(25): 2043-59.